Daily Respiratory Research Analysis

This phase 1b randomized, double-blind, placebo-controlled trial evaluated inhaled LTI-03 at 5 or 10 mg/day for 14 days in 24 patients with idiopathic pulmonary fibrosis. Treatment was well tolerated without severe treatment-related adverse events or airway obstruction, and reduced several profibrotic airway biomarkers, including interleukin-11, thymic stromal lymphopoietin, and, at the higher dose, collagen type 1 alpha 1.

Impact: The study provides early human evidence for a locally delivered, mechanistically targeted antifibrotic therapy in a disease with substantial unmet need. Demonstration of biomarker modulation in bronchial brushings supports biological activity and justifies larger efficacy trials.

Clinical Implications: LTI-03 should not yet be considered standard therapy, but its favorable short-term safety profile and airway biomarker effects support progression to adequately powered, longer-duration trials assessing lung function, progression-free outcomes, and patient-centered endpoints.

Future Directions: Larger multicenter trials should evaluate longer treatment periods, dose-response relationships, pulmonary function decline, exacerbations, radiographic fibrosis, quality of life, and whether airway biomarker changes predict clinical benefit.

This Danish population-based case-control study identified 1,351 patients with pulmonary aspergillosis other than allergic bronchopulmonary aspergillosis and matched them to controls. Inhaled corticosteroids were associated with non-ABPA aspergillosis in a dose-dependent manner, with adjusted incidence rate ratios of 1.7 at doses up to 640 micrograms/day and 2.8 at higher doses. Oral corticosteroids were also associated with both chronic and invasive pulmonary aspergillosis, with adjusted incidence rate ratios of 3.0 and 4.0 across dose categories.

Impact: The study quantifies a clinically important infectious risk associated with both inhaled and systemic corticosteroids using nationwide prescription and disease data. The dose-response pattern may improve risk-benefit assessment and encourage targeted surveillance in patients receiving higher steroid exposure.

Clinical Implications: Clinicians should use the lowest effective corticosteroid dose, reassess prolonged or high-dose exposure, and maintain heightened diagnostic awareness for chronic or invasive pulmonary aspergillosis in patients with compatible symptoms or underlying lung disease. The findings do not establish that corticosteroids should be discontinued when clinically indicated.

Future Directions: Prospective studies should assess absolute risk by underlying disease, steroid dose and duration, concomitant immunosuppression, and inhaler technique, while evaluating whether targeted fungal surveillance or steroid-sparing strategies reduce aspergillosis without compromising respiratory disease control.

This retrospective cohort study analyzed 838,929 US emergency department encounters among adults aged 65 years or older with acute respiratory tract infections for which antibiotics are never appropriate. Antibiotic overuse occurred in 38.5% of encounters, but declined by an estimated 5.0 percentage points over 12 months around the 2016 CDC stewardship milestone and by 15.7 percentage points around the 2020 Joint Commission milestone, although later estimates were less stable.

Impact: The study provides unusually large, contemporary evidence that national stewardship policies can reduce inappropriate antibiotic exposure in a high-risk population. It also demonstrates that substantial residual overuse persists, identifying emergency departments as a continuing target for intervention.

Clinical Implications: Emergency departments should maintain diagnosis-specific outpatient stewardship, clinician feedback, prescribing decision support, and monitoring of antibiotic use for viral or otherwise never-appropriate respiratory diagnoses, particularly in older adults.

Future Directions: Future studies should identify facility-, clinician-, and patient-level drivers of residual overuse and test randomized or stepped-wedge interventions combining rapid diagnostics, communication strategies, audit and feedback, and electronic prescribing support.